Litcius/Paper detail

16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial

Stacy Smith, Neal Bhatia, Stuart D. Shanler, Rebecca DeMoor, Judith Schnyder

2020Journal of the American Academy of Dermatology13 citationsDOI

Topics & Concepts

MedicineAtopic dermatitisOpen labelDermatologySafety profileInternal medicineClinical trialAdverse effectDermatology and Skin Diseases
16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial | Litcius